Sandoz Expands Biologics Capabilities with Acquisition of Just-Evotec Biologics

Sandoz has completed the acquisition of Just-Evotec Biologics EU SAS from Evotec SE. The deal includes a Toulouse site and a license to cutting-edge continuous-manufacturing technology for biosimilars. This expansion aligns with Sandoz's biosimilar strategy, enhancing in-house development and manufacturing capabilities, efficiency, and scalability. The transaction is within existing capital-expenditure commitments and does not impact the company's 2025 guidance.